Current market catalysts

8-K filing — Arrive AI Inc. (ARAI)

Filed: 2026-09-08 AccNo: 0001493152-26-041704 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — RELMADA THERAPEUTICS, INC. (RLMD)

Filed: 2026-09-08 AccNo: 0001213900-26-097851 Size: 187 KB Item 8.01: Other Events

Dyne Therapeutics To Demonstrate Additional One-Year Results From Phase 1/2 ACHIEVE Study Of Zeleciment Basivarsen For DM1 At Annual International Congress Of World Muscle Society

Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present

8-K filing — Longevity Health Holdings, Inc. (XAGEW)

Filed: 2026-09-08 AccNo: 0001437749-26-029755 Size: 163 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Definium Therapeutics, Inc. (DFTX)

Filed: 2026-09-08 AccNo: 0001193125-26-384403 Size: 212 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Strategy Inc (STRD)

Filed: 2026-09-08 AccNo: 0001193125-26-384402 Size: 425 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events

Oracle Could Swing By $47.8 Billion After Earnings

Options markets are pricing big earnings moves for nine stocks, led by AeroVironment, American Eagle, RH, Oracle and other major names.

8-K filing — Sana Biotechnology, Inc. (SANA)

Filed: 2026-09-08 AccNo: 0001193125-26-384405 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Hovde Group Initiates Coverage On Northrim BanCorp with Outperform Rating, Announces Price Target of $30

Hovde Group analyst Brett Rabatin initiates coverage on Northrim BanCorp (NASDAQ:NRIM) with a Outperform rating and announces Price Target of $30.

8-K filing — Strive, Inc. (SATA)

Filed: 2026-09-08 AccNo: 0001628280-26-060809 Size: 311 KB Item 8.01: Other Events

China Renaissance Initiates Coverage On Corning with Buy Rating, Announces Price Target of $238

China Renaissance analyst Jack Zhou initiates coverage on Corning (NYSE:GLW) with a Buy rating and announces Price Target of $238.

Hovde Group Initiates Coverage On Home BancShares with Outperform Rating, Announces Price Target of $34

Hovde Group analyst Edward Najarian initiates coverage on Home BancShares (NYSE:HOMB) with a Outperform rating and announces Price Target of $34.

Samsung Electronics And ASML Announce Expanded Collaboration On High NA EUV Lithography; Samsung Plans High NA EUV Adoption For DRAM High-Volume Manufacturing By 2028, Joins 12-Inch Photomask Initiative

Solaris Energy Infrastructure shares are trading higher after the company announced it raised its Q3 and Q4 adjusted EBITDA guidance.

Canaccord Genuity Maintains Buy on Strategy, Raises Price Target to $179

Canaccord Genuity analyst Joseph Vafi maintains Strategy (NASDAQ:MSTR) with a Buy and raises the price target from $175 to $179.

Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. Novartis obtained global rights to develop, manufacture and commercialize pelacarsen under a license and collaboration agreement with the company.

Why Is Oracle Stock Surging on Tuesday?

Oracle Corp. (NYSE: ORCL) stock surges on Tuesday amid excitement over its upcoming Q1 earnings report and expanding AI infrastructure partnerships.

Pharvaris shares are trading higher after the company announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release tablet for the prevention of HAE attacks.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Philip Morris Intl Raises Preliminary FY2026 Adj EPS Guidance from $8.26-$8.41 to $8.35-$8.50 vs $8.41 Est

Philip Morris Intl (NYSE:PM) raises preliminary FY2026 Adj EPS guidance from $8.26-$8.41 to $8.35-$8.50 vs $8.41 analyst estimate..

Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.

Philip Morris Intl Raises Preliminary Q3 Adj EPS Guidance from $2.20-$2.25 to $2.29-$2.34 vs $2.43 Est

Philip Morris Intl (NYSE:PM) raises preliminary Q3 Adj EPS guidance from $2.20-$2.25 to $2.29-$2.34 vs $2.43 analyst estimate..

Philip Morris Intl Raises Preliminary FY2026 GAAP EPS Guidance from $7.19-$7.34 to $7.28-$7.43 vs $7.75 Est

Philip Morris Intl (NYSE:PM) raises preliminary FY2026 GAAP EPS guidance from $7.19-$7.34 to $7.28-$7.43 vs $7.75 analyst estimate..

Oportun Appoints Bill Franklin As CFO, Effective September 8

Oportun (NASDAQ:OPRT), a mission-driven financial services company, announced that Bill Franklin has joined the Company as Chief Financial Officer, effective today, September 8, 2026. Franklin will lead Oportun's

Guardant Health shares are trading higher after the company announced the FDA approved Guardant360 CDx.

Nebius Just Became Palantir’s Preferred Sovereign AI Infrastructure Partner

Nebius (NBIS) stock jumps 3% premarket after partnering with Palantir (PLTR) for sovereign AI infrastructure. Technicals stay bullish.

AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html

IonQ shares are trading higher after the company announced it published the first complete, end-to-end fault-tolerant resource estimate for running Shor’s algorithm.

Roivant Sciences shares are trading higher after the company announced its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease met its primary endpoint.

8-K filing — GENERAL ELECTRIC CO (GE)

Filed: 2026-09-08 AccNo: 0000950142-26-002501 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits